Recently, Midapace announced the completion of tens of millions of yuan in A+ round of financing, exclusively invested by Wutongshu Capital. This round of financing is mainly used for the clinical, registration, production and sales of neuromodulation product lines. Prior to this, Medapace has completed two rounds of financing. Investors include well-known investment institutions such as Proxima Ventures and Datai Capital, as well as the industrial company Pinchi Medical.
Medapace was established in 2018 by Dr. Chen Jianfeng, and also brought in Dr. Victor Pikov, an international neuromodulation expert and former director of the neuromodulation platform of GSK and Galvani Bioelectronics. Today, Midapex has established an international R&D team and is an international leader in the field of mechanism research and application realization of gastrointestinal neuromodulation.
Midapex entered the medical device market from neuromodulation equipment, and is committed to developing world-leading original neuromodulation therapy in the field of digestive tract and metabolic diseases, providing a full range of solutions from diagnosis to treatment of digestive tract diseases. Its products cover implantable neuromodulation therapy devices (IPGs), diagnostic devices for functional diseases of the digestive tract and wearable neuromodulation therapy devices.
media coverage
The investment world start – up
This article is reprinted from: https://readhub.cn/topic/8hhSrkalchA
This site is for inclusion only, and the copyright belongs to the original author.